NCT06168786View on ClinicalTrials.gov

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 20, 2023

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2027

Conditions
Colorectal Cancer
Interventions
DRUG

Fruquintinib

Fruquintinib:5mg ,qd,po, d1-d14, q3w

DRUG

Cadonilimab

Cadonilimab:10mg/kg, ivgtt, d1, q3w

RADIATION

SBRT

SBRT:8-10Gy×5F，qod， in 10 days

Trial Locations (1)

430000

RECRUITING

Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Huazhong University of Science and Technology

OTHER